Skip to main content

Government News

  • Boehringer Ingelheim India and NIPER Hajipur sign MoU to advance pharmaceutical research and knowledge-led collaboration

    Boehringer Ingelheim India Private Limited and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur today signed a Memorandum of Understanding (MoU) to advance pharmaceutical research, education and innovation. The five-year collaboration will create new pathways for researchers and students in Bihar and the wider region to engage with global-standard open science platforms, joint research initiatives and capability-building programmes thus strengthening the talent pipeline for India’s next phase of pharmaceutical innovation.

  • New Prior Intimation Rule for Drug Export Trials to Take Effect from April 21

    In a regulatory update aimed at streamlining drug export processes, the Central Drugs Standard Control Organization (CDSCO) has announced the implementation of a Prior Intimation System for Form CT-05 applications. The new system will come into force from April 21, 2026, following amendments introduced under Gazette Notification G.S.R. 50(E).

  • DCC refers retail pharmacy deregulation proposals to sub-committee, including removal of pharmacist name from licence

    In a significant step toward easing the regulatory burden on India's retail pharmacy sector, the Drugs Consultative Committee (DCC) at its 68th meeting on 20 March 2026 directed a sub-committee to examine four landmark deregulation proposals. The sub-committee's findings will be placed before the DCC for final deliberation before any rule amendments are made.

  • DTAB Backs Major Reform : All Antimicrobials May Soon Be Classified as “New Drugs” in India

    In a significant development for India’s pharmaceutical regulatory landscape, the Drugs Technical Advisory Board (DTAB) has reaffirmed its position to include all antimicrobial drugs under the definition of “New Drugs” as per the New Drugs and Clinical Trials Rules, 2019.

    The decision was taken during the 93rd meeting of DTAB held on February 16, 2026, at FDA Bhawan, New Delhi, conducted in a hybrid format. The board reviewed and approved the Action Taken Report (ATR) from its previous (92nd) meeting held on April 24, 2025.

  • CDSCO Issues Alert After Theft of Sanofi Lantus Insulin Pens During Transit

    India’s drug regulator has issued a public advisory after a consignment of insulin pens manufactured by Sanofi India Limited was reported stolen during transportation, raising concerns about potential risks if the products enter the market through unauthorized channels.

  • CDSCO Announces Faster NOC Process for Drug Testing Before Approval
    The regulator has announced that companies will now receive the No Objection Certificate, NOC more quickly, helping to streamline regulatory procedures and reduce approval timelines.
  • India and Brazil Sign MoU to Boost Pharmaceutical Regulatory Cooperation
    India and Brazil formalised a partnership to deepen cooperation in the regulation of pharmaceutical and medical products by signing a Memorandum of Understanding (MoU) between India’s Central Drugs Standard Control Organisation (CDSCO) and the Brazilian Health Regulatory Agency (ANVISA).
  • India Transitions to Td Vaccine Under National Immunization Programme
    In a major step to strengthen the country’s immunization framework, Union Health Minister JP Nadda inaugurated the indigenously manufactured Tetanus and Adult Diphtheria (Td) vaccine at the Central Research Institute (CRI), Kasauli
  • CDSCO Approves AstraZeneca’s Imfinzi for Advanced Endometrial Cancer in India
    AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import and market Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL, sold under the brand name Imfinzi, for an additional indication in India.
  • Path Opens for CGHS Pharmacists to Become Gazetted Officers
    In a major and long-awaited development, the Central Government has notified the Recruitment Rules for the posts of Depot Manager (DM) and Assistant Depot Manager (ADM) under the Central Government Health Scheme (CGHS).
Subscribe to Government News